Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Metastatic Hormone-sensitive Prostate Cancer
Related studies linked through entity extraction aliases.
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE3